Q-omics provides the consensus-scored MIR2355 profile across patient tissues and cancer cell-line models. MIR2355 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR2355 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, MIR2355 RNA expression shows 8,221 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UCS, HNSC, and LAML as cancer lineages where MIR2355 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR2355 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR2355 survival associations across molecular data types. MIR2355 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR2355 RNA expression–survival associations across cancer types. High MIR2355 expression shows unfavorable associations in LIHC, CESC, ACC, THYM and THCA, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify UCS as the clearest survival context for MIR2355 RNA expression.
This table summarizes MIR2355 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR2355. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR2355 shows lower tumor expression in BRCA and LUAD and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher MIR2355 RNA expression in tumor versus normal tissue (log2 FC = +0.238, t-test p < 0.001).
This table shows molecular features associated with MIR2355 in patient tissues and cancer cell lines. In patient samples, MIR2355 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
